Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
    2.
    发明授权
    Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them 失效
    磺酰胺取代的稠合的7-元环化合物,它们作为药物的用途,以及包含它们的药物制剂

    公开(公告)号:US06333349B1

    公开(公告)日:2001-12-25

    申请号:US09342597

    申请日:1999-06-29

    IPC分类号: A61K31335

    摘要: The present invention relates to compounds of formula I, in which X1, X2, X3, X4, Y1, Y2, Y3, Y4, R(3), R(4) and R(5) have the meanings mentioned in the specification, their preparation and their use, in particular in pharmaceuticals. The compounds effect the potassium channel or the IKs channel opened by cyclic adenosine monophosphate (cAMP) and are outstandingly suitable as pharmaceutical active compounds, for example for the prophylaxis and therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal disorders.

    摘要翻译: 本发明涉及式Ⅰ化合物,其中X1,X2,X3,X4,Y1,Y2,Y3,Y4,R(3),R(4)和R(5) 他们的准备和使用,特别是在药物。 这些化合物影响钾通道或由环磷酸腺苷(cAMP)打开的IK通道,并且非常适合作为药物活性化合物,例如用于预防和治疗心血管疾病,特别是心律不齐,用于治疗胃肠道溃疡 地区或治疗腹泻病。

    Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
    5.
    发明授权
    Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them 失效
    磺酰胺取代的稠合的7-元环化合物,它们作为药物的用途,以及包含它们的药物制剂

    公开(公告)号:US06908947B2

    公开(公告)日:2005-06-21

    申请号:US09983670

    申请日:2001-10-25

    摘要: The present invention relates to compounds of formula I, in which X1, X2, X3, X4, Y1, Y2, Y3, Y4, R(3), R(4) and R(5) have the meanings mentioned in the specification, their preparation and their use, in particular in pharmaceuticals. The compounds effect the potassium channel or the IKs channel opened by cyclic adenosine monophosphate (cAMP) and are outstandingly suitable as pharmaceutical active compounds, for example for the prophylaxis and therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal disorders.

    摘要翻译: 本发明涉及式Ⅰ化合物,其中X1,X2,X3,X4,Y1,Y2,Y3,Y4,R(3),R(4)和R(5) 他们的准备和使用,特别是在药物。 这些化合物影响由环磷酸腺苷(cAMP)打开的钾通道或IκS通道,并且非常适合作为药物活性化合物,例如用于预防和治疗心血管疾病,特别是心律失常, 用于治疗胃肠道区域的溃疡或用于治疗腹泻病症。

    Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
    9.
    发明授权
    Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them 有权
    磺酰胺取代的苯并二氢吡喃染料,其制备方法,它们作为药物或诊断剂的用途,以及包含它们的药物

    公开(公告)号:US06191164B1

    公开(公告)日:2001-02-20

    申请号:US09258289

    申请日:1999-02-26

    IPC分类号: A01N4316

    CPC分类号: A61K31/353

    摘要: Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or a diagnostic, and medicament comprising them Chromans of the formula I and of the formula 1a having the meanings R(A), R(B), R(C) and R(1) to R(8) indicated in the claims are outstandingly suitable for preparing a medicament for blocking the K+ channel which is opened by cyclic adenosine monophosphate (cAMP); and further for preparing a medicament for inhibiting gastric acid secretion; for the treatment of ulcers of the stomach and of the intestinal region, in particular of the duodenum, for the treatment of reflux esophagitis, for the treatment of diarrheal illnesses, for the treatment and prevention of all types of arrhythmias including ventricular and supraventricular arrhythmias, and for the control of reentry arrhythmias and for the prevention of sudden heart death as a result of ventricular fibrillation.

    摘要翻译: 磺酰胺取代的苯并二氢吡喃染色剂,其制备方法,它们作为药物或诊断剂的用途,以及包含它们的药物式I和式1的色素具有R(A),R(B),R(C)和R 1)至权利要求所述的R(8)非常适用于制备用于封闭由环磷酸腺苷(cAMP)打开的K +通道的药物; 并进一步制备用于抑制胃酸分泌的药物; 用于治疗胃和肠道区域,特别是十二指肠的溃疡,用于治疗反流性食管炎,用于治疗腹泻疾病,用于治疗和预防所有类型的心律失常,包括室性和室上性心律失常, 并且用于控制再入心律失常和由于心室颤动而预防心脏死亡。